おすすめの製品
由来生物
mouse
品質水準
抗体製品の状態
purified antibody
抗体製品タイプ
primary antibodies
クローン
2B, monoclonal
形状
liquid
含みます
≤0.1% sodium azide as preservative
化学種の反応性
human
メーカー／製品名
Calbiochem®
保管条件
OK to freeze
アイソタイプ
IgG2b
輸送温度
wet ice
保管温度
−20°C
ターゲットの翻訳後修飾
unmodified
遺伝子情報
human ... BRCA2(675)
詳細
Anti-BRCA2 (Ab-1), mouse monoclonal, clone 2B, recognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. It is validated for Western blotting and immunoprecipitation.
Purified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with myeloma cells. Recognizes the ~460 kDa BRCA2 protein.
Recognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
免疫原
Human
a recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
アプリケーション
Immunoblotting (2 µg/ml)
Immunoprecipitation (2 µg)
Immunoprecipitation (2 µg)
包装
Please refer to vial label for lot-specific concentration.
警告
Toxicity: Standard Handling (A)
物理的形状
In PBS.
再構成
Following initial thaw, aliquot and freeze (-20°C).
アナリシスノート
Positive Control
MCF7 cells
MCF7 cells
その他情報
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA95, 13869.
Connor, F., et al. 1997. Nat. Genet.17, 423.
Sharan, S.K., et al. 1997. Nature386, 804.
Ludwig, T., et al. 1997. Genes Dev.11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol.184, 385.
Suzuki, A., et al. 1997. Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol.23, 1.
Goggins, M., et al. 1996. Cancer Res.56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet.5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet.12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res.56, 4590.
Wooster, R., et al. 1995. Nature378, 789.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA95, 13869.
Connor, F., et al. 1997. Nat. Genet.17, 423.
Sharan, S.K., et al. 1997. Nature386, 804.
Ludwig, T., et al. 1997. Genes Dev.11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol.184, 385.
Suzuki, A., et al. 1997. Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol.23, 1.
Goggins, M., et al. 1996. Cancer Res.56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet.5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet.12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res.56, 4590.
Wooster, R., et al. 1995. Nature378, 789.
The CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
法的情報
Sold under license of U.S. Patents 5,837,492 and 6,124,104.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類コード
11 - Combustible Solids
WGK
WGK 1
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
OP95-100UG:
OP95-MG:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
M Goggins et al.
Cancer research, 56(23), 5360-5364 (1996-12-01)
Germline mutations in BRCA2 predispose carriers to the development of breast, ovarian, and a variety of other cancers. The original localization of the BRCA2 gene was aided by its homozygous deletion in a pancreatic carcinoma; indeed, an excess of pancreatic
A K Wong et al.
The Journal of biological chemistry, 272(51), 31941-31944 (1998-01-24)
Recent work has shown that the murine BRCA2 tumor suppressor protein interacts with the murine RAD51 protein. This interaction suggests that BRCA2 participates in DNA repair. Residues 3196-3232 of the murine BRCA2 protein were shown to be involved in this
F Connor et al.
Nature genetics, 17(4), 423-430 (1997-12-17)
Germline mutation of the BRCA2 gene carries a high risk of developing breast cancer. To study the function of this gene, we generated a mutation in Brca2 in mice. Unlike other mutations in the Brca2 gene, which are lethal early
J V Rajan et al.
Developmental biology, 184(2), 385-401 (1997-04-15)
Germline mutations in the putative tumor suppressor gene, BRCA1, predispose women to dramatically elevated risks of breast cancer, while germline mutations in the structurally unrelated gene, BRCA2, predispose both men and women to breast cancer. Recent studies have suggested an
S V Tavtigian et al.
Nature genetics, 12(3), 333-337 (1996-03-01)
Breast carcinoma is the most common malignancy among women in developed countries. Because family history remains the strongest single predictor of breast cancer risk, attention has focused on the role of highly penetrant, dominantly inherited genes in cancer-prone kindreds (1).
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）